Omeros (NASDAQ:OMER) inks an agreement with Basel, Switzerland-based Lonza Group (OTCPK:LZAGF) for the commercial production of narsoplimab (OMS721). Financial terms remain confidential.
The company is preparing marketing applications in the U.S. and Europe for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.